Amgen (NASDAQ:AMGN) Updates FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 21.700-23.100 for the period, compared to the consensus earnings per share estimate of 22.290. The company issued revenue guidance of $37.1 billion-$38.5 billion, compared to the consensus revenue estimate of $37.8 billion.

Wall Street Analyst Weigh In

Several research firms have weighed in on AMGN. Mizuho increased their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Daiwa Securities Group increased their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Jefferies Financial Group began coverage on Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Wells Fargo & Company increased their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Finally, Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $356.62.

Amgen Stock Up 2.4%

Shares of AMGN stock traded up $8.23 during trading hours on Thursday, hitting $346.25. 3,587,935 shares of the company’s stock traded hands, compared to its average volume of 2,266,551. The stock’s fifty day simple moving average is $358.07 and its two-hundred day simple moving average is $340.45. Amgen has a 12-month low of $261.43 and a 12-month high of $391.29. The stock has a market cap of $186.86 billion, a price-to-earnings ratio of 24.33, a PEG ratio of 3.34 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.74 by $0.41. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the business earned $4.90 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts expect that Amgen will post 22.16 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results: Amgen reported EPS of $5.15 vs. consensus ~$4.74 and revenue of $8.62B vs. ~$8.58B — beats on both lines and sales rose ~4%, supporting the near‑term earnings story. Amgen’s (NASDAQ:AMGN) Q1 CY2026 sales top estimates
• Positive Sentiment: Mgmt commentary/slides: Management framed 2026 as a “springboard” year and highlighted six growth drivers; investors may take this as confidence in product mix and pipeline execution. Amgen (AMGN) Q1 2026 Earnings Transcript
• Positive Sentiment: Pipeline progress: Amgen is advancing a broader development program for weight‑loss candidate MariTide and submitted a label update to the FDA for an autoimmune drug — signs of R&D activity that could drive medium‑term growth. Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
• Neutral Sentiment: Guidance: FY‑2026 EPS guidance set to 21.700–23.100 (consensus ~22.29); revenue guidance $37.1B–$38.5B (consensus ~37.8B) — range leaves room for beats or misses, which could sustain volatility as analysts model the year. Amgen Q1 press release and slide deck
• Neutral Sentiment: Analyst sentiment: Wall Street remains moderately optimistic on targets but Amgen has underperformed the market over the past year — analysts will reassess models after the quarter. What Are Wall Street Analysts’ Target Price for Amgen Stock?
• Negative Sentiment: Tavneos regulatory risk: An FDA advisory panel raised efficacy/data concerns for Tavneos and there have been reports of a proposed U.S. withdrawal — this is a material downside catalyst for a rare‑disease franchise and could pressure sentiment until resolved. Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

Hedge Funds Weigh In On Amgen

Hedge funds have recently added to or reduced their stakes in the company. Sfam LLC purchased a new position in Amgen in the 4th quarter worth approximately $38,000. Advocate Investing Services LLC purchased a new position in Amgen in the 4th quarter worth approximately $39,000. Garton & Associates Financial Advisors LLC purchased a new position in Amgen in the 4th quarter worth approximately $52,000. Itau Unibanco Holding S.A. raised its holdings in Amgen by 21.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 189 shares of the medical research company’s stock worth $62,000 after acquiring an additional 33 shares during the last quarter. Finally, State of Wyoming purchased a new position in Amgen in the 4th quarter worth approximately $65,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.